France (FR)

close-button

Project Types

Third Party Funds Group - Overall project
Third Party Funds Group - Sub project
Third party funded individual grant
Internally funded project
FAU own research funding: EFI / IZKF / EAM ...
Non-FAU Project

Status

Project year

From
To
Erstellung der End-to-End Simulatorsoftware für die Instrumente der THESEUS-Mission THESEUS (Transient High Energy Sky and Early Universe Surveyor) mission June 1, 2024 - Sept. 30, 2026 Humane autologe Zellkultursysteme zur Untersuchung neuartiger RNA-basierter Nanopartikel als Therapeutikum gegen Lungenkrebs (TumorOUT) Humane autologe Zellkultursysteme zur Untersuchung neuartiger RNA-basierter Nanopartikel als Therapeutikum gegen Lungenkrebs April 1, 2023 - March 31, 2026 An AI-based framework for visualizing and analyzing massive amounts of 4D tomography data for beamline end users (KI4D4E) March 1, 2023 - Feb. 28, 2026 SiC composite claddings: LWR performance optimization for nominal and accident conditions (SCORPION) SiC composite claddings: LWR performance optimization for nominal and accident conditions Sept. 1, 2022 - Feb. 28, 2026 International Research Network (IRN) in Representation Theory (2021-2025) (IRN) International Research Network in Darstellungstheorie Jan. 1, 2021 - Dec. 31, 2025 Reduced Complexity Techniques and Performance Analysis towards 6G Cell-Free Massive MIMO (CellFree6G) Sept. 1, 2022 - Sept. 1, 2025 Textile Recycling Excellence (T-REX) Textile Recycling EXcellence May 31, 2022 - May 31, 2025 Scaling up Local physical Activity policy monitoRinG initiativEs (LARGE) (LARGE) Jan. 1, 2024 - Dec. 31, 2024 Clinical traslatio of FLASHKNiFE, a promising device for ultrahigh dose-rate radiation therapy (FLASHKNiFE) (ST-EUC-EIT-09_FLASHKNiFE 2024) Jan. 1, 2024 - Dec. 31, 2024 Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation. (NeutroCure) Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation. Jan. 1, 2020 - Dec. 31, 2024